trial

The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia

NCTId NCT05011669
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 200 (actual)
Sponsored by Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Primary completion 2023-04-16
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
200 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2021-08-16
Primary completion
2023-04-16
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Lurasidone

Sponsors

Marubeni Pharmaceuticals (Suzhou) Co., Ltd.Lead Sponsor

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
200
Phase
PHASE4
Primary Completion Date
2023-04-16
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication